<DOC>
	<DOCNO>NCT01035385</DOCNO>
	<brief_summary>This study multicenter , open-label , randomize , control phase III study compare preoperative postoperative FOFLOX4 chemotherapy postoperative FOFLOX4 chemotherapy patient resectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Compare FOFLOX4 Preoperative Postoperative Postoperative Resectable Liver Metastasis Colorectal Cancer ( MCC )</brief_title>
	<detailed_description>To investigate three-year progression free survival ( PFS ) advantage FOLFOX4 treatment resectable metastatic colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Resectable liver metastasis colorectal cancer ( distance tumor lower edge anal 12cm ) , visible extrahepatic metastatic tumor . Curable resection , determine surgeon image physician . The minimum liver metastasis need ≥2cm . Patients recruit meet condition : Primary tumor remove metachronous liver metastasis patient residue eye microscope . Primary tumor remove 1 month simultaneous liver metastasis patient . 2 . Age of≥18 ≤80 3 . ECOG≤2 4 . Signed write informed consent 1 . Peripheral neuropathy ( CTC＞1 ) 2 . Had neurological mental disorder 3 . Active infection 4 . Allergy Platinumbased drug 5 . Other acute disease include infection , heartdisease ( CHF , stable unstable angina ) 6 . Pregnant nursing patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>FOFLOX4</keyword>
	<keyword>resectable liver metastasis colorectal cancer</keyword>
</DOC>